Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Oxidative Cyclization-Induced Activation of a Phosphoinositide 3-Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics.

Zhu H, Mishra R, Yuan L, Abdul Salam SF, Liu J, Gray G, Sterling AD, Wunderlich M, Landero-Figueroa J, Garrett JT, Merino EJ.

ChemMedChem. 2019 Nov 20;14(22):1933-1939. doi: 10.1002/cmdc.201900481. Epub 2019 Nov 7.

PMID:
31696673
2.

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1434. doi: 10.1158/1078-0432.CCR-18-4267. No abstract available.

PMID:
30770493
3.

Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma.

Yuan L, Mishra R, Patel H, Abdulsalam S, Greis KD, Kadekaro AL, Merino EJ, Garrett JT.

J Cancer. 2018 Nov 24;9(24):4665-4676. doi: 10.7150/jca.27295. eCollection 2018.

4.

Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

Garrett JT, Chakrabarty A, Arteaga CL.

Oncotarget. 2018 Aug 17;9(64):32400. doi: 10.18632/oncotarget.26017. eCollection 2018 Aug 17.

5.

HER3 signaling and targeted therapy in cancer.

Mishra R, Patel H, Alanazi S, Yuan L, Garrett JT.

Oncol Rev. 2018 May 16;12(1):355. doi: 10.4081/oncol.2018.355. eCollection 2018 Jan 30.

6.

Activating HER3 mutations in breast cancer.

Mishra R, Alanazi S, Yuan L, Solomon T, Thaker TM, Jura N, Garrett JT.

Oncotarget. 2018 Jun 12;9(45):27773-27788. doi: 10.18632/oncotarget.25576. eCollection 2018 Jun 12.

7.

Genomic alterations of ERBB receptors in cancer: clinical implications.

Mishra R, Hanker AB, Garrett JT.

Oncotarget. 2017 Nov 30;8(69):114371-114392. doi: 10.18632/oncotarget.22825. eCollection 2017 Dec 26. Review.

8.

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL.

Clin Cancer Res. 2017 Aug 1;23(15):4323-4334. doi: 10.1158/1078-0432.CCR-16-2287. Epub 2017 Apr 5. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1434.

9.

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.

Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL.

J Clin Invest. 2014 Dec;124(12):5490-502. doi: 10.1172/JCI72573. Epub 2014 Nov 17.

10.

An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.

Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA.

Cancer Res. 2013 Oct 1;73(19):6024-35. doi: 10.1158/0008-5472.CAN-13-1198. Epub 2013 Aug 8.

11.

Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.

Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL.

Cancer Res. 2013 Oct 1;73(19):6013-23. doi: 10.1158/0008-5472.CAN-13-1191. Epub 2013 Aug 5.

12.

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.

Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL.

Clin Cancer Res. 2013 Feb 1;19(3):610-9. doi: 10.1158/1078-0432.CCR-12-2024. Epub 2012 Dec 5.

13.

Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

Garrett JT, Chakrabarty A, Arteaga CL.

Oncotarget. 2011 Dec;2(12):1314-21. Erratum in: Oncotarget. 2018 Aug 17;9(64):32400.

14.

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.

Miller TW, Rexer BN, Garrett JT, Arteaga CL.

Breast Cancer Res. 2011;13(6):224. doi: 10.1186/bcr3039. Epub 2011 Nov 1. Review.

15.

ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.

Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, Horak ID, Arteaga CL.

Cancer Res. 2011 Jun 1;71(11):3941-51. doi: 10.1158/0008-5472.CAN-10-3775. Epub 2011 Apr 11.

16.

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.

Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5021-6. doi: 10.1073/pnas.1016140108. Epub 2011 Mar 8.

17.

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.

Garrett JT, Arteaga CL.

Cancer Biol Ther. 2011 May 1;11(9):793-800. Epub 2011 May 1. Review.

18.

Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.

Allen SD, Garrett JT, Rawale SV, Jones AL, Phillips G, Forni G, Morris JC, Oshima RG, Kaumaya PT.

J Immunol. 2007 Jul 1;179(1):472-82.

19.

Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.

Garrett JT, Rawale S, Allen SD, Phillips G, Forni G, Morris JC, Kaumaya PT.

J Immunol. 2007 Jun 1;178(11):7120-31.

20.

Atomic force microscopy visualization of poly(urethane urea) microphase rearrangements under aqueous environment.

Agnihotri A, Garrett JT, Runt J, Siedlecki CA.

J Biomater Sci Polym Ed. 2006;17(1-2):227-38.

PMID:
16411611
21.

Understanding Indian children, learning from Indian elders.

Garrett JT.

Child Today. 1993-1994;22(4):18-21, 40. No abstract available.

PMID:
8033595
22.

The industrial back problem: role of the industrial hygienist and ergonomics.

Garrett JT, Ahmad I.

Am Ind Hyg Assoc J. 1977 Oct;38(10):560-2.

PMID:
144434
23.

The changing role of the industrial hygienist.

Ahmad I, Garrett JT.

Am Ind Hyg Assoc J. 1977 Mar;38(3):142-4. No abstract available.

PMID:
860688
24.

The anatomy of an in-transit spill.

Garrett JT.

J Water Pollut Control Fed. 1971 May;43(5):773-8. No abstract available.

PMID:
5553780
25.

A review of exposures to oil mist.

HENDRICKS NV, COLLINGS GH, DOOLEY AE, GARRETT JT, RATHER JB Jr.

Arch Environ Health. 1962 Feb;4:139-45. No abstract available.

PMID:
13906424
26.

A comparison of two methods for correcting for self-absorption of beta particles, using sulfur.

SCHWEITZER GK, GARRETT JT.

J Phys Colloid Chem. 1951 Feb;55(2):195-9. No abstract available.

PMID:
14825119

Supplemental Content

Loading ...
Support Center